Aquestive therapeutics strengthens team to align with strategic focus on allergy space

Warren, n.j., aug. 10, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of timothy e. morris to the company's board of directors, effective august 5, 2022, and kenneth truitt, m.d., as chief medical officer effective september 6, 2022.   aquestive's board of directors will now be comprised of seven directors, six of whom are independent directors.   mr. morris has been appointed to the audit committee of the board of directors.
AQST Ratings Summary
AQST Quant Ranking